NCT06478823 Healthy Stool Volunteer Donors for Fecal Microbiota Transplantation Trials
| NCT ID | NCT06478823 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Gastro-Intestinal Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-07-08 |
| Primary Completion | 2030-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-07-08 with a primary completion date of 2030-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Currently, ANSM recommendations govern FMT (Fecal Microbiota Transplantation) in clinical trials. The collection and validation of these stool donations as part of the trials is complex and not very efficient. It therefore seems essential to identify the limiting factors and the characteristics of Healthy Volunteer Donors to optimize the number of valid stool donations.
Eligibility Criteria
Inclusion Criteria: \- Age ≥ 18 years and \< 50 years * 17 kg/m² \< body mass index \< 30 kg/m² * Regular bowel movement defined as at least 1 stool every other day and maximum 2 stools per day * Subject with health insurance (AME excepted) * Informed written consent Exclusion Criteria: Definitive non-inclusion criteria: 1. Infectious risk : \- Known HIV, HBV, HCV, HTLV infection \- Residence of more than 2 years in the intertropics zone within the previous 5 years \- Hospitalization abroad for more than 24 hours in the last 12 months (including a member of the healthy volunteers donor's entourage) \- Risk factors for Creutzfeldt-Jakob disease (history: treatment with extractive growth hormone, a family case of transmissible spongiform subacute encephalopathy, surgery with opening of the dura or neurosurgery or invasive brain exploration before 1 January 1995, stay in United Kingdom for a duration greater than 1 year cumulatively between 1980 and 1996 or the presence of neurological or neuropsychiatric scalable recent clinical signs) * Previous history of typhoid fever, tuberculosis and malaria * Past or current injection drug user or regular use of other drug 2. Gastrointestinal disease: \- Personal or 1st degree family history of: inflammatory bowel disease or celiac disease \- Personal history of irritable bowel syndrome, idiopathic chronic constipation or chronic diarrhea \- Previous history of gastrointestinal neoplasia or polyps \- Family history of 1st degree gastrointestinal neoplasia or polyps before age 60 3. 1st degree family history of one of the following autoimmune or inflammatory disease : inflammatory arthritis, psoriasis, multiple sclerosis, type I diabetes, spondylitis, lupus and Basedow disease \- If family history unknown in the first degree, the donor is not eligible 4. Previous history of : * Subject prone to hemorrhoids (at least 1 event within the previous 1 year) * Subject with an active chronic illness (except active chronic mild allergic disease o (example: allergic rhinitis, chronic eczema…)) * Diagnosis of Gilbert's syndrome done by screening is not a chronic disease. The healthy volunteer donor will therefore remain eligible. * Serious allergy requiring hospitalization within the previous 12 months * Curative long-term treatment * Severe allergy requiring hospitalization in the last 12 months * Allogeneic human or animal tissue or organ transplant * 5- Factors that may affect the composition of the intestinal microbiota: * Special Diet (example: gluten-free...) * Lactose-free, vegetarian and vegan diets are permitted. * Pregnancy or breastfeeding * Taking immunosuppressants (eg calcineurin inhibitors, corticosteroids, biological agents, etc.) * Antineoplastic chemotherapy 6- Subject under legal protection 7- Participation in any other interventional study except studies for stool donation Temporary non-inclusion criteria 1. Infectious risk : * Unprotected sexual intercourse with a new partner in the previous 4 months and/or sexual intercourse with several different persons within the previous 4 months * sexual partner who has had more than 1 partner within the previous 4 months and/or * sexual transmitted infection within the previous 4 months (healthy volunteer donor himself or sexual partner) * Sexual relationship in exchange for money or drugs in the last 12 months. (healthy volunteer donor himself or sexual partner) * Sexual relationship with a partner with positive serology for HIV, viral hepatitis B or C, in the last 6 months. * Sexual relationship with a partner who has used intravenous drugs, doping substances * Hospitalization abroad for more than 24 hours in the last 12 months (healthy volunteer or entourage) * Travelling within the previous 3 months except : Germany, Austria, Belgium, Spain, Finland, Ireland, Italia, Luxembourg, Netherland, Portugal, Greece, Slovenia, Cyprus, Malta, Slovakia, Estonia , Bulgaria, Croatia , Hungary, Latvia , Lithuania, Poland , Romania, Czech Republic, the United Kingdom, Denmark, Norway, Sweden, Switzerland, USA or Canada. * Blood transfusion, piercing (including earrings) or tattoo within the previous 4 months * Surgery (all types) or hospitalization within the previous 4 months * Person living under the same roof with an infectious or contagious disease (i.e who have been hospitalized) within the previous 4 months * Blood exposure accident (for wound, pricking or projection ...) within the previous 4 months * Dental care within the previous 7 days * Gastroenteritis within the previous 3 months (defined by acute onset of diarrhea (\> 3 soft or liquid stools per day) and duration \< one week) * Episode of infection or skin infection/lesion within the previous 15 days 2-Risk linked to Covid-19 * Confirmed infection in the previous 28 days (after symptoms have ceased) * Clinical signs of suspected infection (chill, cough, fever, dyspnea, myalgia, asthenia, malaise, pharyngeal pain, anosmia , ageusia, rhinorrhea, chest pain, headache, diarrhea) in the previous 28 days (after the end of symptoms) * Having been in risky contact (according to the definition of Santé Publique France with a person whose infection is confirmed or suspected: "14 days after the last risky contact: if the recommended screening tests in the event of risky contact between D15-D28 are negative "In the 28 days preceding inclusion in the absence of a screening test. Healthcare professionals using recommended protective measures with COVID patients are not considered high-risk contacts 3- Monkeypox risk * Confirmed or suspected infection within the previous 42 days ( after beginning of symptoms) * Risky contact with a person with confirmed or suspected infection within the previous 21 days (from the date of last contact) * Person who received the vaccine Imvanex within the previous 28 days ( after the last injection). 4- vaccination in the previous 15 days 5- Factors that may affect the composition of the intestinal microbiota: * Taking antibiotic or antifungal (oral) in the previous 3 months before donation * Taking non-steroidal anti-inflammatory drugs (oral) in the previous month before donation * Taking corticosteroids (oral) in the previous 4 weeks before donation. Corticosteroids allowed if taken more than 4 weeks before donation. and not for an autoimmune or inflammatory disease. Temporary or permanent exclusion criteria: \- At each visit of the donation period, the temporary or definitive exclusion criteria (identical to the temporary or definitive non-inclusion criteria) will be rechecked
Contact & Investigator
Mélissa Montil
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT06478823 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 49 Years, studying Gastro-Intestinal Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06478823 currently recruiting?
Yes, NCT06478823 is actively recruiting participants. Contact the research team at melissa.montil@aphp.fr for enrollment information.
Where is the NCT06478823 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06478823 clinical trial?
NCT06478823 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Mélissa Montil at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 400 participants.